Ignite Creation Date:
2024-05-06 @ 6:09 PM
Last Modification Date:
2024-10-26 @ 2:42 PM
Study NCT ID:
NCT05566834
Status:
RECRUITING
Last Update Posted:
2023-10-18
First Post:
2022-09-22
Brief Title:
Minnelide Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer
Sponsor:
Minneamrita Therapeutics LLC
Organization:
Minneamrita Therapeutics LLC
Study Overview
Official Title:
A Phase 1 Open-Label Dose-Escalation Safety Pharmacokinetic and Pharmacodynamic Study of Minnelide Capsules Given Alone or in Combination With Paclitaxel in Patients With Advanced Gastric Cancer
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase 1 Open-label Dose-Escalation Safety Pharmacokinetic and Pharmacodynamic Study of Minnelide Capsules given alone or in combination with paclitaxel in patients with Advanced Gastric Cancer
Detailed Description:
Minnelide is a water soluble disodium salt variant of triptolide a diterpenoid an HSP70 inhibitor Studies using orthotopic pancreatic cancer cell lines and human xenograft transplants demonstrate that Minnelide prevents tumor progression increases survival and causes tumor regression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None